Sign In
News Digest /
Ticker: AZN
Ticker: AZN
07:06am, Monday, Feb 23, 2026
AstraZeneca (ST: AZN) secures FDA approval for Calquence combined with venetoclax, offering a fixed-duration oral treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma based on robust Phase III results.
07:23am, Monday, Feb 09, 2026
Delayed January jobs data, January CPI inflation, December retail sales, and earnings from Cisco, Coca-Cola, McDonald's among key market catalysts this week.
07:16am, Wednesday, Jan 28, 2026
FTSE 100 dips 0.4% as pharma and bank stocks retreat; FTSE 250 gains ground. Gold prices rally, energy shares up on oil boost, luxury brands stumble on weak earnings reports.
09:34am, Wednesday, Dec 17, 2025
Compugen Ltd. (NASDAQ:CGEN) gains 12.8% premarket after a $65M upfront royalty deal with AstraZeneca (NASDAQ:AZN) tied to cancer drug rilvegostomig's future sales and milestones.
07:38am, Tuesday, Dec 02, 2025
AstraZeneca's baxdrostat, targeting resistant hypertension, enters FDA priority review with a decision expected by Q2 2026, following strong Phase III results showing notable blood pressure reduction.
09:02am, Wednesday, Nov 26, 2025
FDA approves AstraZeneca's immunotherapy Imfinzi (durvalumab) combined with chemotherapy for certain early-stage stomach and gastroesophageal junction cancers, showing improved survival rates in a large Phase III trial.
04:44am, Tuesday, Oct 28, 2025
Novartis CEO Vas Narasimhan insists major acquisitions remain on the table, spotlighting the $12B Avidity deal amid a strong cash flow and steady sales growth despite generic pressure.
07:58am, Monday, Oct 27, 2025
Jefferies upgrades AstraZeneca (LSE: AZN), forecasting robust growth in oncology and biopharma that could push revenues to $80 billion by 2030, lifting price targets significantly.
06:26am, Thursday, Aug 07, 2025
The Trump administration is urging pharma firms to raise drug prices overseas, especially in Europe, to lower U.S. costs, pushing "most favored nation" pricing amid complex trade talks and industry resistance to domestic price cuts.
06:25am, Tuesday, Jul 22, 2025
AstraZeneca (NASDAQ: AZN) plans a new U.S. plant in Virginia, boosting domestic production amid supply chain challenges. This strategic move aims to enhance logistics, secure supply lines, and strengthen its footprint in the competitive pharma manufacturing race.
05:26am, Monday, Mar 17, 2025
AstraZeneca (NASDAQ: AZN) plans to acquire EsoBiotec for up to $1 billion, enhancing its cell therapy capabilities in oncology and autoimmune disorders. The deal includes $425M upfront and $575M based on milestones, with potential market impacts for investors.
09:28am, Monday, Feb 03, 2025
Investors eagerly await earnings reports this week from key players like Google, Toyota, Amazon, Alibaba, Eli Lilly, and Merck. These results will provide critical insights into the technology, automotive, and pharmaceutical sectors, influencing market dynamics.
04:19am, Friday, Jan 17, 2025
AstraZeneca's Calquence gains FDA approval as the first BTK inhibitor for untreated mantle cell lymphoma, promising improved survival rates. This milestone enhances AstraZeneca's oncology portfolio, signaling potential growth opportunities for investors.
05:01am, Tuesday, Nov 12, 2024
AstraZeneca (NASDAQ: AZN) raises 2024 sales and earnings forecast after strong Q3 performance, driven by oncology demand. The firm plans a $3.5B US investment, despite stock fluctuations amid China concerns. Growth strategies position it well in the healthcare sector.
04:20am, Monday, Nov 11, 2024
This week (Nov 11-17, 2024) brings critical earnings reports from major companies such as Home Depot, AstraZeneca, Cisco, Disney, and Alibaba. Investors should watch for insights into consumer spending and tech trends, impacting market shifts.
03:02am, Thursday, Jul 25, 2024
AstraZeneca (NASDAQ: AZN) raises its 2024 revenue and profit forecasts, fueled by a 19% sales surge in oncology.
05:51am, Friday, Jun 14, 2024
AstraZeneca (NASDAQ: AZN) shines with a robust oncology portfolio, highlighted by significant advances in treatments like Tagrisso and promising CAR-T therapies for liver cancer. CFO Aradhana Sarin emphasizes strong future prospects, aiming for $80B revenue by 2030.
08:40am, Tuesday, May 21, 2024
AstraZeneca (NYSE: AZN) plans to boost its revenue to $80 billion by 2030 with new drugs in oncology, biopharmaceuticals, and rare diseases, focusing on innovative cancer treatments.